Tempus Acquires Personalis for $1.5 Billion

Company Tempus AI Event Type M&A / Acquisition Modality Tumor-Informed MRD Testing / AI-Enabled Precision Oncology Platform Personalis (NeXT Personal MRD Test) Indication Oncology (Pan-Tumor, Recurrence Monitoring) Summary Tempus AI agreed to acquire Personalis for $16.25 per share, representing an enterprise value of approximately $1.5…